Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,579.66
(
-0.68%
)
US TECH 100
23,546.80
(
-1.05%
)
Dow Jones
45,857.72
(
-0.79%
)
Brent Oil
105.22
(
-1.28%
)
Bitcoin
69,737.22
(
-2.11%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 132484

Tuesday, 12/17/2013 7:45:24 PM

Tuesday, December 17, 2013 7:45:24 PM

Post# of 257259
BIIB/Samsung* will develop anti-TNF FoB’s in Europe:

http://finance.yahoo.com/news/biogen-idec-samsung-bioepis-announce-070000638.html

Although this PR doesn’t specify which anti-TNF FoB’s are under development, clinicaltrials.gov shows trials in progress for Remicade and Enbrel biosimilars.

See #msg-74411298 for information about pricing of these products.

Curiously, MRK is not mentioned in this PR even though it joined up with Samsung Bioepis in Feb 2013 (#msg-84781042).

*d/b/a Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now